The benzophenanthridine alkaloid fagaronine induces erythroleukemic cell differentiation by gene activation

Planta Medica

Volumn 71, Issue 6, 2005, Pages 489-494

  Dupont, Claude ^a   Couillerot, Eric ^b   Gillet, Reynald ^a   Caron, Catherine ^a   Zeches Hanrot, Monique ^a   Riou, Jean François ^a   Trentesaux, Chantal ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Erythroid gene expression; Fagaronine; GATA 1 transcription factor; K562 cell differentiation; Leukemia

Indexed keywords

ALPHA GLOBIN; BENZOPHENANTHRIDINE DERIVATIVE; ERYTHROPOIETIN RECEPTOR; FAGARONINE; GAMMA GLOBIN; HEMOGLOBIN; MESSENGER RNA; PORPHOBILINOGEN DEAMINASE; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2;

ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHROLEUKEMIA CELL; GENE ACTIVATION; GENE CONTROL; GENE MUTATION; HEME SYNTHESIS; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; PROMOTER REGION; REPORTER GENE; RUTACEAE; UPREGULATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIFFERENTIATION; DNA PRIMERS; DNA-BINDING PROTEINS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; ERYTHROPOIESIS; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION; HUMANS; K562 CELLS; NF-E2 TRANSCRIPTION FACTOR; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PHENANTHRIDINES; PHYTOTHERAPY; PLANT ROOTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; ZANTHOXYLUM;

FAGARA ZANTHOXYLOIDES;

EID: 21344446141     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864147     Document Type: Article

References (21)

1. Reiss M, Gamba-Vitalo C, Sartorelli AC. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 1986; 70: 201-18
2. Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, Castaigne S, Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-53
3. Trentesaux C, Ngo Nyoung M, Aries A, Morceau F, Ronchi A, Ottolenghi S, Jardillier JC, Jeannesson P. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells. Leukemia 1993; 7: 452-7
4. Aries A, Trentesaux C, Ottolenghi S, Jardillier JC, Jeannesson P, Doubeikovski A. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Blood 1996; 87: 2885-90
5. Morceau F, Chenais B, Gillet R, Jardillier JC, Jeannesson P, Trentesaux C. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Cell Growth Diff 1996; 7: 1023-9
6. Comoë L, Jeannesson P, Trentesaux C, Desoize B, Jardillier JC. The antileukemic alkaloid fagaronine and the human K 562 leukemic cells: effects on growth and induction of erythroid differentiation. Leuk Res 1987; 11: 445-51
7. Messmer WM, Tin-WA M, Fong HHS, Bevelle C, Farnsworth NR, Abraham DJ, Trojanek J. Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci 1972; 61: 1858-9
8. Sethi VS. Inhibition of mammalian and oncornavirus nucleic acid polymerase activities by alkoxybenzophenantridine alkaloids. Cancer Res 1976; 36: 2390-5
9. Pezzuto JM, Antosiak SK, Messmer WM, Slaytor MB, Honig GR. Interaction of the antileukemic alkaloid, 2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c] phenanthridine (fagaronine), with nucleic acids. Chem Biol Interact 1983; 43: 323-39
10. Casiano Torres CA, Baez A. Effects of the antitumor drugs 3-nitrobenzothialozo[3,2-a]quinolium and fagaronine on nucleic acid and protein synthesis. Biochem Pharmacol 1986; 35: 679-85
11. Larsen AK, Grondard L, Couprie J, Desoize B, Comoë L, Jardillier JC, Riou JF. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 1993; 46: 1403-12
12. Fleury F, Sukhanova A, Ianoul A, Devy J, Kudelina I, Duval O, Alix AJ, Jardillier JC, Nabiev I. Molecular determinants of site-specific inhibition of human DNA topoisomerase 1 by fagaronine and ethoxidine. Relation to DNA binding. J Biol Chem 2000; 275: 3501-9
13. Tan GT, Lee S, Lee IS, Chen J, Leitner P, Bersterman JM, Kinghorn AD, Pezzuto JM. Natural-product inhibitors of human DNA ligase I. Biochem J 1996; 314: 993-1000
14. Sethi ML. Inhibition of reverse-transcriptase activity by benzophenantridine alkaloids. J Nat Prod 1979; 42: 187-96
15. Tan GT, Pezzuto JM, Kinghorn AD, Hughes SH. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J Nat Prod 1991; 54: 143-54
16. Sorensen BS, Jensen PB, Sehested M, Jensen PS, Kjeldsen E, Nielsen OF, Alsner J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem Pharmacol 1994; 47: 2105-10
17. Leonard M, Brice M, Engel JD, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation. Blood 1993; 82: 1071-9
18. Privitera E, Schiro R, Longoni D, Ronchi A, Rambaldi A, Bernasconi S, Ottolenghi S, Masera G, Biondi A. Constitutive expression of GATA-1, EPOR, α-globin, and γ-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. Blood 1995; 86: 323-8
19. Gillet R, Devemy E, Dupont C, Billat C, Jeannesson P, Trentesaux C. Evidence of the role of protein kinase C during aclacinomycin induction of erythroid differentiation in K 562 cells. FEBS Lett 1999; 454: 331-4
20. Warrell RPJ, He L, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-5
21. Mann KK, Rephaeli A, Colosimo AL, Diaz Z, Nudelman A, Levovich I, Jing Y, Waxman S, Miller Jr WH. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol Cancer Res 2003; 1: 903-12